| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.5M | — | -66.7% |
| SG&A Expense | $6.6M | — | -39.3% |
| Operating Income | -$11.2M | — | +54.6% |
| Income Tax | $0 | — | — |
| Net Income | -$10.3M | — | +55.9% |
| EPS (Basic) | -$0.21 | — | +56.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $86.6M | -9.3% | -26.2% |
| Current Assets | $88.0M | -10.0% | -26.8% |
| Total Assets | $108.4M | -8.4% | -23.1% |
| Current Liabilities | $40.1M | -8.5% | +203.1% |
| Total Liabilities | $40.2M | -8.5% | +202.1% |
| Stockholders' Equity | $68.1M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.9M | — | +21.7% |
| Financing Cash Flow | -$51K | — | -156.7% |
| -46.6% |